Alì Mirazimi

This study identifies a dual-antigen CCHFV vaccine candidate that induces neutralizing immunity and protects against lethal viral challenge.

This study shows that ISG15-USP18 signaling limits viperin-dependent metabolic antiviral restriction by stabilizing USP18 and reducing viperin expression, thereby inhibiting viral replication.

This study identifies MED13 and DDX60 as critical host factors for SARS-CoV-2 infection through a haploid genetic screen in mouse cells.

This study uses metabolomics to compare metabolic responses to SARS-CoV-2 infection and different vaccines in ferrets, revealing distinct metabolic signatures linked to immune responses and vaccine efficacy.

This study uses bat epithelial organoids to investigate antiviral immunity differences between bats and humans, revealing unique interferon responses and implications for viral pathogenesis.

This paper shows that clinical-grade soluble ACE2 effectively inhibits multiple SARS-CoV-2 variants, including VOCs, in cell cultures and across independent labs.

The paper shows clinical grade recombinant ACE2 effectively neutralizes SARS-CoV-2 Omicron in VeroE6 cells, outperforming neutralization against reference isolates.

This paper presents a method for genome-wide spatial mRNA analysis in FFPE tissues, demonstrating its ability to delineate anatomical regions and analyze transcriptomic signatures in ovarian carcinosarcoma.

The paper identifies two lectins, Clec4g and CD209c, that bind to conserved glycosylation sites on SARS-CoV-2 Spike and reduce viral infections.